Placebo for Enlicitide

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HypercholesterolemiaHyperlipidemiaLipoprotein(a)

Phase 2

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

RecruitingNCT07614984

Merck Sharp & Dohme LLCLipoprotein(a)

Start: 2026-06-30End: 2027-10-12Target: 750Updated: 2026-07-20

Phase 3

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

CompletedNCT06450366

Merck Sharp & Dohme LLCHypercholesterolemia

Start: 2024-07-08End: 2025-03-28Updated: 2026-03-27

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Active, not recruitingNCT07216482

Merck Sharp & Dohme LLCHyperlipidemia

Start: 2025-11-11End: 2027-03-01Target: 975Updated: 2026-06-25